Development of antibody-drug conjugates (ADCs) continues to gain momentum across oncology indications. Junshi Biosciences reported successful Phase 3 results for JS005, an IL-17A monoclonal antibody, achieving primary endpoint improvements in moderate-to-severe psoriasis and preparing submissions to Chinese regulators. In lung cancer, Summit Therapeutics and collaborators demonstrated efficacy and challenges for ivonescimab combined with chemotherapy in EGFR-positive NSCLC, with efficacy varying by geography. Such developments highlight evolving roles for ADCs and bispecific antibodies as precision therapeutics in both oncology and immune-mediated diseases.